Nanoparticle-enhanced innovative anticancer multicomponent combinations as adjunct modality for the NSCLC Proton Therapy

Abstract

This study explores the cytotoxic potential of copper oxide (CuO) nanoparticles in non-small cell lung cancer (NSCLC) cells, specifically the A549 cell line. CuO nanoparticles were tested alone and in combination with clinically approved chemotherapeutic agents, including osimertinib, paclitaxel, and cisplatin. Using the MTT assay to assess cell viability, the results demonstrated that CuO nanoparticles significantly enhanced the cytotoxic effects of these drugs, particularly when combined with osimertinib. The findings suggest that such nanoparticle–drug combinations may offer improved selectivity and efficacy, presenting a promising strategy to overcome resistance and reduce systemic toxicity in NSCLC treatment.